BioNTech and Gilead Sciences Announce Clinical Trial Collaboration for Triple-Negative Breast Cancer Treatment

BioNTech SE and Gilead Sciences, Inc. have entered into a clinical trial collaboration to study the combination of BioNTech’s Pumitamig and Gilead’s Sacituzumab Govitecan for treating triple-negative breast cancer (TNBC). This partnership will advance the global Phase 3 ROSETTA Breast-01 study, which is the first to evaluate this combination as a first-line therapy for patients with low or negative PD-L1 expression. The collaboration aims to enhance treatment outcomes for patients with locally advanced or metastatic TNBC.